Manhattan Institute

Prescription Drugs and Price Controls

10 Blocks Podcast

John Tierney joins City Journal editor Brian Anderson to discuss what the debate over prescription drugs gets wrong and the cost that government-imposed price controls could have on one of the world’s most innovative industries.

The business practices of the pharmaceutical industry—or “Big Pharma”—are one of the most divisive political issues of our time. Leaders from both political parties, from Bernie Sanders to President Trump, regularly denounce drug companies for profiteering and call for lower drug prices. But as Tierney notes in City Journal, “of every dollar that Americans spend on health, only a dime goes for prescription drugs. The lion’s share of health spending goes to hospitals and people in the health-care professions.”

America has been called the “Pharmacy to the World” because it’s where more than half of new drugs get developed and tested in clinical trials. Patients in Europe and elsewhere enjoy the benefits of these breakthrough drugs. Price controls in the U.S. would significantly curtail new research and development projects—resulting in a net loss for everyone.

More from Manhattan Institute

Manhattan Institute1 min readPolitics
The U.S.–China Trade War Heats Up
Milton Ezrati joins Paul Beston to discuss escalating trade tensions between the United States and China. The Trump administration announced new tariffs on $300 billion worth of Chinese goods last week, prompting China to order its state-owned busine
Manhattan Institute3 min read
Re-sinking CUNY
The City University of New York moves to eliminate objective testing—reversing the very reforms that had pulled it out of a long decline.
Manhattan Institute3 min read
In Government Property We Trust
Burdened with sky-high and still-rising government-pension costs, states have sought creative ways to come up with new revenue. Some ideas, like an Illinois proposal to borrow more than $100 billion and invest the money in the stock market, have been